Page 3 - Operations Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ -- Weatherford International plc (NASDAQ: WFRD) ("Weatherford" or the "Company") announced today its results for the third quarter of 2021. Third...

Published: May 10, 2021 NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021. “We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the F...

AXS-07 for migraine, NDA submission (2Q 2021) AXS-05 for smoking cessation, FDA meeting (3Q 2021) AXS-05 for MDD, commercial launch, if approved (2H 2021) Clinical Trial Readouts: Clinical Trial Initiations: Upcoming Scientific Conferences International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021 American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021 American Headache Society (AHS) annual meeting, June 3-6, 2021 Upcoming Investor Conferences BofA Health Care Conference, May 11, 2021 (to be webcast) RBC Capital Mar...

Share this article Share this article HOUSTON, May 5, 2021 /PRNewswire/ -- Weatherford International plc (OTC Pink: WFTLF) ("Weatherford" or the "Company") announced today its results for the first quarter of 2021. Revenues for the first quarter of 2021 were $832 million, a decline of 1% sequentially and 32% year-on-year.  Reported operating loss was $13 million in the first quarter of 2021, compared to an operating loss of $107 million in the fourth quarter of 2020 and an operating loss of $822 million in the first quarter of 2020. The Company's first-quarter 2021 net loss was $116 milli...

Published: Mar 01, 2021 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020. “The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported po...